GALT Galectin Therapeutics Inc.
$3.33▼ -5.54%
Healthcare
Other
Volume 76.1K
Avg Volume (10D) 197.3K
Key Metrics & Fundamentals
Market Cap
$335.33M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.03 - 7.13
% vs 50 MA
-7.83%
% vs 200 MA
9.76%
RSI-14
46.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.74
Free Cash Flow
-$2.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.95M
COGS
–
Operating Exp
$3.98M
Operating Income
-$3.98M
EBIT
-$3.98M
Pretax Income
-$9.11M
Net Income
-$9.11M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
GlobeNewswire · Oct 6, 2026 8:00 AM ET
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 10, 2026 8:00 AM ET
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
PR Newswire · Aug 24, 2026 10:31 AM ET
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 14, 2026 8:00 AM ET
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
GlobeNewswire · Aug 4, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GALT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.